Acute cardiac care & resuscitationCohort study
DanGer shock criteria and outcomes in acute myocardial infarction-related cardiogenic shock treated with Impella: the J-PVAD registry
- Retrospective registry cohort study
- nationwide
Authors' conclusion
In this nationwide registry, one-third of AMI-CS patients treated with Impella met DanGer shock criteria. Outcomes in non-eligible subgroups were heterogeneous
Study context
- Population
- AMI-related cardiogenic shock patients treated with Impella, nationwide Japanese J-PVAD registry, 2020–2023
- Participants
- 3,975 patients
- Exposure
- DanGer shock-eligible vs -ineligible AMI-CS subgroups treated with Impella
- Outcome
- Mortality
- Follow-up
- 30 days
Main finding
As reported in the abstract
30-day mortality
| Group | Value | Share of all AMI-CS | Without return of spontaneous circulation |
|---|---|---|---|
| Eligible STEMI-CS | 37.6% | 35.6% | |
| Non-eligible STEMI-CS | 27.6% | ||
| OHCA | 51.3% | 63.4% | |
| MC | 39.8% | ||
| Non-STEMI-CS (NSTEMI-CS) | 33.3% |
Observational data: associations, not effects.
Further findings
Risk factors for mortality in non-eligible STEMI-CS
- Mortality increased significantly with advanced age, renal dysfunction, VA-ECMO use, ventricular arrhythmia or sepsis
Original publication
DanGer shock criteria and outcomes in acute myocardial infarction-related cardiogenic shock treated with Impella: the J-PVAD registry. Eur Heart J. Published 13 October 2025. doi:10.1093/eurheartj/ehaf787
Summarised from the published abstract; every number is checked against it